Decreased expression of the interleukin 2 receptor on CD8 recipient lymphocytes in intestinal grafts rendered tolerant by liver transplantation in rats

S Sarnacki, H Nakai, D Calise, T Azuma, N Brousse, Y Révillon, N Cerf-Bensussan

Abstract

Background—In a previous study, it was shown that a spontaneously tolerated DA (RT1a) liver allograft in a PVG (RT1c) recipient was able to induce tolerance of a DA small bowel graft performed 17 days later in spite of infiltration of the intestinal grafts by mononuclear cells.

Aims—to compare the phenotype of graft infiltrating cells in rejecting and tolerated small bowel grafts in order to elucidate the mechanism(s) which block the graft infiltrating cells from mediating rejection.

Methods—Multiparameter immunofluorescence was used to compare the phenotype and state of activation of donor and recipient cells isolated from intestinal grafts rejected or tolerated after liver transplantation.

Results—Three differences were found. Firstly, there was a more rapid replacement of lamina propria (LP) cells by recipient lymphocytes in tolerated than in rejected grafts. Secondly, the proportion of LP recipient CD8αβ+ lymphocytes bearing the high affinity receptor for interleukin 2 was significantly less in tolerated grafts (1.1%, range 0–2%) than in rejected grafts (21.3%, range 9–26%). Finally, tolerated grafts contained significantly less NK lymphocytes (NKR-P1+) and macrophages than rejected intestinal allografts.

Conclusions—These observations make it possible to delineate clear cut differences in the phenotype of cells infiltrating rejecting versus tolerated grafts. Furthermore, the data suggest that liver transplantation induces tolerance of intestinal grafts by hampering the activation of recipient TcRαβ+ CD8αβ+ T cells and subsequently the recruitment of non-specific effector cells.

Keywords: liver transplantation; small bowel transplantation; tolerance; intestinal T lymphocytes; interleukin 2 receptor; rat

In 1965, Garnier et al reported that liver grafts transplanted between outbred pigs survived spontaneously.1 Acceptance of liver allografts was then reported by Calne et al and found to be associated with the development of a state of donor specific unresponsiveness towards simultaneous heart or kidney grafts.2 Rejection of skin grafts, on the other hand, could be delayed but not prevented, even when performed two weeks after a successful liver transplant.3 These findings were further investigated in the rat model. Kamada showed that PVG (RT1c) rats grafted orthotopically with a DA (RT1a) liver became tolerant to simultaneous DA heart and kidney grafts or to a subsequent DA skin graft.4 Finally, in the same rat strain combination, we have shown that liver transplantation induced the indefinite survival of a small bowel graft performed 17 days after the liver graft.4 The protective effect of the liver against allograft rejection is strongly suggested but less clearly shown in humans5–8 and might be particularly interesting in the case of small bowel transplantation. Indeed a combined liver and small bowel transplantation is indicated in 60% of cases because of the liver injury induced by long term parenteral nutrition. A better understanding of the mechanism by which the liver graft can induce tolerance of small bowel grafts should be useful to guide immunosuppressive regimens and to improve follow up of patients with combined liver and small bowel transplants.

Although several studies have investigated the problem, the mechanism underlying liver induced tolerance to donor alloantigens remain elusive. It is unrelated to changes in Th1/Th2 subsets.9–10 The tolerogenic effect of a microchimerism resulting from the migration of a small number of liver derived donor cells into recipient lymphoid organs was hypothesised but not proved.11–15 Clonal deletion of donor specific alloreactive cytotoxic T cells and a potential role of soluble MHC class I antigens was suggested by Kamada.5 A recent study showing that in vitro, soluble MHC class I antigens induced the apoptosis of alloreactive cytotoxic T cells, provided a rationale for this hypothesis.15 Using liver grafts bearing the Mls8 superantigens, Dahmen et al were however unable to confirm this hypothesis.16

In our model of combined liver and small bowel transplantation, we observed that tolerance was obtained in spite of a striking mononuclear cell infiltration of the lamina propria in the intestinal graft. This infiltration was transitory, as by day 150, the intestinal allografts had recovered a nearly normal histological appearance.1 In order to define criteria useful to distinguish the infiltrate in tolerant and rejecting grafts and thereby to obtain an insight into the mechanism(s) which blocked graft infiltrating cells from rejection, we have now used multiparameter immunofluorescence analysis to investigate the phenotype and state
of activation of donor and recipient cells isolated from intestinal allografts.

**Materials and methods**

**ANIMALS**

Adult DA (RT1a) and PVG (RT1c) rats, 7–9 weeks old, were used as donors and recipients respectively. Animals were purchased from CNRS (Orléans, La Source, France) and Harlan Olac (Bicester, UK) and raised under conventional conditions. All animals were maintained under standard conditions and received water and rodent chow ad libitum. All procedures involving rats were conducted according to the guidelines of the National Institute of Health’s Guide for the Care and Use of Laboratory Animals (Bethesda, Maryland, USA).

**HEPATIC TRANSPLANTATION**

Orthotopic whole liver transplantation was performed using the cuff technique as previously described with a modification for the revascularisation of the hepatic artery. Briefly, the suture for the arterial anastomosis was inserted 2 mm from the end of the donor receiving vessel and pulled through the open end. A small superficial tangential “bite” of the host artery was taken one wall thickness from the cut end and the suture returned into the donor receiving vessel, emerging as close as possible to the first suture entry, thus resulting in invagination of the host artery into the donor vessel. The anastomosis was secured by a superficial suture placed in the adventitia 180° opposite to the first suture. The recipient anhepatic phase was 17 (1) minutes and the total cold ischaemia time was 75 (8) minutes.

**INTESTINAL TRANSPLANTATION**

Heterotopic auxiliary small bowel transplantation was performed by the method described by Monchik and Russell. Briefly, a 15 cm long proximal small bowel graft was dissected free from 1 cm beyond the ligament of Treitz. The donor’s superior mesenteric artery and portal vein were Anastomosed to the recipient aorta and inferior vena cava, respectively, in an end to side fashion using 10/0 and 11/0 nylon sutures. Both graft ends were brought out as enterostomies. All surgical procedures were performed aseptically under ether anaesthesia. The mean (SD) cold ischaemia time of the grafts was 130 (10) minutes. The mean aorta and infrahepatic vena cava clamping time was 60 (5) minutes.

Animals that died within two days of transplantation were excluded from further analyses.

**EXPERIMENTAL DESIGN**

DA small bowel grafts were transplanted either into naive PVG rats or into PVG rats which had received a DA liver graft 17 days before small bowel transplantation. This two step combination of liver/small bowel transplantation leads to indefinite liver and small bowel graft survival (more than 150 days) whereas, in the same donor/recipient strain combination, small bowel grafted alone is consistently rejected on day 8 (1). Syngeneic DA-DA and PVG-PVG small bowel grafts were also studied. Preliminary studies showed no significant difference in the phenotype of cells isolated from lamina propria of PVG-PVG or DA-DA syngeneic grafts except for the proportion of NKR-P1+ natural killer (NK) cells, which was higher in DA-DA syngeneic grafts than in PVG-PVG grafts (9% versus 1.5%). Therefore in subsequent studies, syngeneic PVG-PVG grafts were used as controls, except for the study of NK cells where comparison was performed with both DA-DA and PVG-PVG grafts.

**PREPARATION OF GRAFT INFILTRATING CELLS**

Recipient rats were sacrificed on days 2, 5, 6, 7 and in the group with rejecting small bowel grafts, on days 2, 5, and 45 after intestinal transplantation in the group with tolerated small bowel grafts following liver transplantation, and on day 5 in the group with syngeneic small bowel grafts. In each recipient, cells were isolated from lamina propria (LP) and mesenteric lymph nodes (MLN).

Single cell suspensions were prepared from MLN in RPMI-1640 medium (Gibco, Grand Island, New York, USA) supplemented with 10% newborn calf serum (Gibco). Briefly, specimens were passed through a wire mesh and cell suspensions were spun on Ficoll-Hypaque (Pharmacia, Saint-Quentin-en-Yvelines, France) at 1800 g for 15 minutes to eliminate dead cells.

LP lymphocytes were isolated according to a previously described procedure. After removal of PP, fat, and mesentery, the grafts were flushed with phosphate buffered saline (PBS), opened longitudinally, and cut into small pieces. Mucus was further removed by gentle rubbing and the mucosa was scraped. The fragments were stirred in 199 medium (Gibco) supplemented with 20% newborn calf serum and 1 mM dithioerythritol (Sigma Chemical Co., St. Louis, Missouri, USA) for 15 minutes to dissolve mucus, washed twice with PBS, and resuspended in PBS supplemented with 0.1% glucose and 0.78 mM EDTA (Bioprobe Systems, Montreuil-sous-Bois, France) and then agitated in a 37°C water bath to remove epithelial cells and intraepithelial lymphocytes; the latter procedure was repeated three times. The remaining fragments were incubated with RPMI at 37°C for five minutes, washed twice with PBS, and then stirred in RPMI supplemented with 10% fetal calf serum (Gibco) and 90 U/ml collagenase (type C-2139, Sigma) for 60 minutes. Fragments were then disrupted with a syringe. After sedimentation to eliminate debris, the supernatant of collagenase treated fragments was purified by Ficoll gradient (Nycor Prep 1.077 Animal, Nycomed Pharma AS, Oslo, Norway) to remove dead cells. Preparation of LP cells contained less than 0.5% epithelial cells.

**FLOW CYTOMETRY**

Mouse monoclonal antibodies against rat CD4 (W3/25), CD8α (MRC OX8), CD8β (341), TG1αβ (R 73), IL-2-R p55 γ chain (MRC OX-39), NKR-P1 antigen (specific for natural killer cells) (3.2.3), and PVG MHC class I (MRC OX-27) were obtained from Serotec.
Cells were analysed on an FACScan flow cytometer (Becton Dickinson) using LYSIS II software (Becton Dickinson). Electronic gates were set using side (SSC) and forward (FSC) scatter parameters in order to analyse mononuclear cells and exclude granulocytes and epithelial cells.

**RESULTS**

**MIGRATION OF CELLS OF RECIPIENT ORIGIN**

Figure 1 shows the appearance of lymphocytes of recipient origin in MLN and LP of rejecting and tolerated grafts. On day 2, in rejecting as well as in tolerated grafts, 60–70% of LP and MLN lymphocytes were already of recipient origin. However, on day 5, the proportion of lymphocytes of recipient origin was significantly higher in tolerated than in rejected grafts. The difference was even more pronounced in the lamina propria (p=0.004) than in MLN (p=0.02). On day 45, the proportion of lymphocytes of recipient origin was over 95% in the LP of tolerated grafts (data not shown).

**PROPORTION OF TcR\alpha-\beta+ AND CD8\alpha-\beta+ T LYMPHOCYTES OF RECIPIENT ORIGIN IN LP**

In syngeneic PVG grafts on day 5, approximately 55% of isolated lymphocytes were TcR\alpha-\beta+, 45% CD4+, and only 5% CD8\alpha-\beta+ (fig 2). In rejecting grafts, on day 5, the proportion of TcR\alpha-\beta+ cells among recipient lymphocytes was 60% with a proportion of CD8\alpha-\beta+ cells that increased significantly to 30% (p=0.049). As the yield of cells extracted from LP was not significantly different between rejecting and syngeneic grafts, the proportion of TcR\alpha-\beta+ cells tended to increase (p=0.56) and that of PVG CD4+ cells to decrease (p=0.12) when compared with syngeneic grafts, although not significantly.

In tolerated grafts, the proportions of recipient TcR\alpha-\beta+ and CD8\alpha-\beta+ lymphocytes, 79% and 45% respectively on day 5, were significantly increased when compared with syngeneic grafts (p=0.025 and p=0.033). This increase was at least as important as that observed in rejecting grafts (fig 2). As in rejecting grafts, this increased proportion reflected a significant increase in the absolute number of TcR\alpha-\beta+ and CD8\alpha-\beta+ lymphocytes. Indeed, the yield of extracted cells in these tolerated grafts was highly variable (median 18\times10^6, range 4.9–26.3\times10^6) but comparable to that observed in syngeneic and rejecting grafts (p=0.10 and p=0.22). On day 45, the proportion and the absolute number of PVG
EXPRESSION OF CD25 ON RECIPIENT LP T LYMPHOCYTES

The state of activation of the various subsets of lymphocytes infiltrating rejecting and tolerated intestinal grafts was analysed by studying their expression of CD25 (IL-2R) (see table 1). Multiparameter immunofluorescence was used to compare CD25 expression according to the phenotype and origin of extracted lymphocytes. PVG/DA chimerism was different in rejecting and tolerated animals (see earlier). In addition the high percentage of CD25+ cells among donor DA cells remaining in both rejecting (72.5%, range 69.3–93.2%) and tolerated (83%, range 80–86%) grafts hampered the analysis of the recipient cells involved in the process of allogeneic rejection.

Whereas the differences in the proportion of recipient TCRαβ+ and CD4+ lymphocytes expressing CD25 cells between syngeneic, rejecting, and tolerated intestinal grafts were not significant, the expression of CD25 varied on recipient CD8αβ+ lymphocytes in rejecting and tolerated grafts. On day 5, 2.5% of PVG lymphocytes extracted from syngeneic grafts were CD8αβ+ CD25+. This proportion was less than in normal unmodified PVG rats (6.7%, range 3.5–9.5; p=0.033), probably due to the lack of exposure of the heterotopic graft to intraluminal antigens. In rejecting grafts, 21% of recipient lymphocytes were CD8αβ+ CD25+, a proportion significantly higher than in syngeneic grafts (p<0.05). In contrast, in tolerated grafts only 1% of CD8αβ+ lymphocytes of recipient origin expressed CD25, a proportion significantly less than in rejecting grafts (p<0.05). This proportion remained low on day 45 as only 4% (range 1.6–7%) of recipient cells were CD8αβ+ CD25+. This proportion was significantly lower than in normal unmodified PVG rats (6.7%, range 3.5–9.5; p=0.033), probably due to the lack of exposure of the heterotopic graft to intraluminal antigens. In rejecting grafts, 21% of recipient lymphocytes were CD8αβ+ CD25+, a proportion significantly higher than in syngeneic grafts (p<0.05). In contrast, in tolerated grafts only 1% of CD8αβ+ lymphocytes of recipient origin expressed CD25, a proportion significantly less than in rejecting grafts (p<0.05). This proportion remained low on day 45 as only 4% (range 1.6–7%) of recipient cells were CD8αβ+ CD25+ (data not shown).

STUDY OF MACROPHAGES AND NK CELLS
Numbers of natural killer cells in syngeneic, rejecting, and tolerated intestinal grafts were compared on day 5 using the NKR-P1 marker. In rats, NKR-P1 is mainly expressed by natural killer cells with a higher expression in DA than in PVG strains.24 This antigen can also be

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Expression of CD25 on intestinal graft infiltrating T cells of recipient origin on day 5†‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Syngeneic graft‡</td>
</tr>
<tr>
<td>TCRαβ+CD25+</td>
<td>22% (20–31) (n=3)</td>
</tr>
<tr>
<td>CD8αβ+CD25+</td>
<td>2.5% (2–2.5) (n=3)</td>
</tr>
<tr>
<td>CD4+CD25+</td>
<td>10% (16–28) (n=3)</td>
</tr>
<tr>
<td>NKR-P1+CD25+</td>
<td>0.8% (0–5) (n=3)</td>
</tr>
<tr>
<td>PVG+CD25+</td>
<td>30% (24–36) (n=3)</td>
</tr>
</tbody>
</table>

†Data are percentage of positive cells among graft infiltrating cells of recipient origin (median, range). n = number of animals analysed.
‡The percentage of cells of recipient origin (median, range) were determined in rejected and tolerated grafts using the OX-27 biotinylated monoclonal antibody as indicated in methods. In syngeneic grafts cells of donor and recipient origin could not be distinguished and immunofluorescence was performed on total cells.
*p<0.05 (Mann-Whitney U test).
expressed by activated neutrophils and by a very small subset of T cells.\textsuperscript{25} Labelling of granulocytes (rare in rejecting grafts before day 7, see later) was excluded by setting the analysis gate on lymphocytes. In rejecting grafts, there was a significant increase in the proportion of NKRP-1\textsuperscript{+} cells of recipient (PVG) origin as compared with syngeneic PVG or DA grafts (p<0.05) (fig 2).

In contrast, in tolerated grafts on day 5, the proportion of recipient NKRP\textsuperscript{1+} lymphocytes was significantly less that in rejecting grafts (p=0.033). It was higher than in PVG syngeneic grafts (p=0.033) but comparable to that observed in DA syngeneic grafts (p=0.15) (fig 2). Therefore, these results suggest that intestinal graft rejection is associated with a recruitment of NK cells which does not occur or is notably reduced in tolerated grafts.

The presence of macrophages in intestinal grafts was revealed by the ED2\textsuperscript{+} monoclonal antibody on tissues sections using immunohistochemistry. On day 3, there was a moderate infiltration of ED2\textsuperscript{+} cells in the pericryptic region of the LP and in the muscular layers of rejecting grafts. From day 5 and thereafter, this infiltration increased in the muscular layer, around the hyperplasic crypts, and within the axis of the villus in the LP. On day 9, when the process of rejection was almost complete with total villous atrophy and extensive gland destruction, the massive infiltration of the remaining structure of the grafts was essentially made of ED2\textsuperscript{+} cells and granulocytes (fig 3A).

In contrast, in tolerated grafts, no recruitment of ED2\textsuperscript{+} cells and/or granulocyte cells was observed either on day 5 and 9 after transplantation or at any time during the follow up of tolerated grafts (fig 3B).

Expression of MHC class II antigens by intestinal epithelial cells was studied in tissue sections using OX-6 and F17–32. Rejection was associated with early and persistent expression of MHC class II antigens on crypt epithelium, ...
which contrasted with a loss of their normal expression on the villous epithelium after day 5 (fig 4A). In tolerated grafts, there was also an early appearance of MHC class II antigens on crypt epithelium but they remained normally expressed on the villous epithelium. This diffuse expression of MHC class II antigens persisted until day 150 (fig 4B).

Discussion

This work shows three differences between intestinal grafts rejected or tolerated following liver transplantation. Firstly, there was a more rapid replacement of LP cells by recipient lymphocytes in tolerated than in rejected grafts. Secondly, the LP of both rejected and tolerated intestinal grafts was infiltrated by comparable numbers of recipient TCRαβ+ CD8αβ+ T cells but the proportion of recipient CD8αβ+ lymphocytes bearing the high affinity receptor for interleukin 2 (IL-2), CD25, was significantly less in tolerated grafts. Finally, in tolerated grafts, the numbers of NKR-P1+ lymphocytes and of macrophages were notably reduced.

Only a few studies have examined the phenotype of graft infiltrating cells in liver induced tolerance. One study showed a significant increase in the number of B cells in tissue sections of tolerated liver grafts but no change in T cell subsets or macrophages. A second study failed to identify phenotypical changes specific for rejected or tolerated liver grafts. Particularly, expression of the high affinity IL-2 receptor (CD25) on tissue sections or by flow cytometry was comparable in both types of liver grafts. Bishop et al studied the phenotype of cells infiltrating cardiac grafts tolerised by liver transplantation using immunohistochemistry on tissue sections. As in our study, tolerated cardiac grafts were massively infiltrated by T cells but not by macrophages. In both rejected and tolerated grafts, a large number of cells expressed CD25 although the authors suggested that there may be fewer positive cells in tolerated grafts. In our study, the use of multiparameter fluorescence analysis on isolated cells allowed us to analyse CD25 expression according to the phenotype and the origin of the cells. CD25 expression was very high on donor cells in both rejected and tolerated intestinal grafts. This high expression of CD25 on donor cells has been previously reported and was ascribed to a graft versus host reaction of donor cells against recipient alloantigens. On recipient cells, expression of CD25 was not significantly decreased on CD4+ lymphocytes but was strikingly less on recipient CD8αβ+ lymphocytes isolated from tolerated grafts. This result suggests that the tolerance process specifically affected the recipient CD8αβ+ T lymphocytes.

On the one hand, activated alloreactive CD8αβ+ cells might have been deleted in the liver and thus could be undetectable in the intestinal graft. This has been documented in a model of TCR transgenic mice where strong induction of MHC class I antigens on hepatocytes resulted in the deletion of the alloreactive transgenic CD8+ T cells. Deletion of alloreactive T cells following liver transplantation has been initially suggested by several groups but remains controversial. Decreased alloreactive cytotoxic T cell activity has been observed, associated in one recent report with a high level of apoptosis of graft infiltrating cells. However, a complete deletion of alloreactive cytotoxic T cell is unlikely as vigorous mixed lymphoid reaction and significant donor specific cytotoxic T lymphocyte activity could still be generated in long term tolerant recipients. Furthermore, recent work in mice by Dahmen failed to show deletion of alloreactive T cells after liver transplantation.

On the other hand, the absence of proliferating recipient T cells in the graft associated lymphoid organs (data not shown) and the lack of CD25 expression on the recipient CD8αβ+ T cells infiltrating the graft LP suggests a defect in the activation of allogeneic CD8αβ+ T lymphocytes. A previous study has emphasised the role of the donor antigen presenting cells present in the graft in the early phase of acute rejection. Therefore, the accelerated replacement of donor cells observed in the tolerated grafts may hamper the activation of allogeneic T cells. However, expression of CD25 on CD4+ recipient T cells was comparable in rejecting and tolerated grafts arguing against this hypothesis. Alternatively, allogeneic CD8αβ+ lymphocytes might have been rendered unresponsive by the liver transplantation. This hypothesis is supported by the recent observation in another rat model, that spontaneous acceptance of a liver graft can be prevented by the injection of recombinant IL-2. Such an anergic state could affect T cell mediated cytotoxicity as well as production of cytokines or chemokines. In our model, the early and persistent expression of MHC class II antigens on the crypt cells in tolerated grafts suggested the activation of donor antigen presenting cells. However, interferon γ was not notably affected. However, the lack of recruitment of macrophages and NK cells in tolerated grafts may indicate decreased production of chemokines.

In conclusion, these observations strongly suggest that liver transplantation induces tolerance of intestinal grafts by hampering the activation of recipient allogeneic TCRαβ+ CD8αβ+ T cells and subsequently reducing the recruitment of non-specific effector cells. Further work will be necessary to define further how the liver graft interferes with the activation of allogeneic T cells. Such studies will be useful to optimise immunosuppression in patients receiving a combined liver and small bowel transplant.

We thank Ibrahim Astachiou for helping us to set up liver transplantation, and Marina Cavazzana-Calvo, J Di Santo, Delphine Guy-Grand, and Alain Fischer for helpful discussions. This work was supported by the Association de Recherche contre le Cancer (ARC), the Institut Électrice Santé, and the Fondation de l’Avenir.